The tiny bits of plastic pollution that make their way from the environment into our bodies accumulate at much higher ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

The drugs are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulins Fiasp and NovoLog. Medicare will announce the next 15 drugs by Feb. 1 and ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

The first round of Medicare prescription drugs negotiations covered Eliquis, Enbrel, Entresto, Farxiga, Fiasp/NovoLog; Imbruvica, Januvia, Jardiance, Stelara and Xarelto. Lower prices of those ...